Skip to main content

Table 3 NanoString counts of individual genes of significance (p values < 0.05), analyzed from tumor core biopsy samples prior to study treatment. Fold change is PR vs PD (baseline)

From: An open-label, pilot study of veliparib and lapatinib in patients with metastatic, triple-negative breast cancer

Gene name PR PD Fold change Affected pathway
CALML5 143.27 2255.68 − 15.74 MAPK
MMP7 453.82 5649.84 − 12.45 WNT
BRCA1 57.16 275.57 − 4.82 DNA damage repair, PI3K
PLA2G3 196.18 41.35 4.74 MAPK
CRYAB 568.51 2587.04 − 4.55 DNA damage repair
COL11A1 65.8 294.98 − 4.48 PI3K
CKB 100.47 438.12 − 4.36 DNA
LFNG 722.24 175.07 4.13 Notch
RASGRF1 41.19 156.18 − 3.79 MAPK
PIK3R3 2009.36 558.36 3.6 JAK/STAT, MAPK, PI3K
SOCS1 362.96 104.85 3.46 JAK/STAT
GJB2 395.9 125.75 3.15 DNA damage repair
PTCH1 23.77 72.6 − 3.05 Hedgehog
STAT1 5748.18 1940.41 2.96 JAK/STAT
COL27A1 81.66 209.94 − 2.57 PI3K
SOCS2 498.48 197 2.53 JAK/STAT
FGFR2 133.74 333.34 − 2.49 MAPK, PI3K
NOTCH1 194.05 439.53 − 2.27 Notch
HGF 181.46 81.94 2.21 MAPK, PI3K